Dx&Vx Secures Latin American Foothold for KRNA Technology

The dual-agreement success highlights the versatility of KRNA, which allows for the long-term storage of nucleic acid-based materials without ultra-cold chain infrastructure. The private-sector deal with the Argentine manufacturer moved rapidly, concluding just one month after the parties met at the BIO International Convention in June. Conversely, the agreement with the public health entity followed a grueling 10-month technical review, underscoring the platform's ability to satisfy both high-speed commercial demands and rigorous public-sector safety standards.

These two contracts bring the company’s total number of material transfer agreements to five. With the Latin American pharmaceutical market projected to reach USD 250.6 billion by 2034, Dx&Vx is targeting regions where tropical climates make traditional cold-chain logistics difficult to maintain. CEO Kwon Kyu-Chan emphasized that securing a partner in the public procurement space provides a strategic foundation for future licensing-out achievements. Partners will now initiate internal stability testing on the platform, a prerequisite for formalizing long-term commercial integration.